NCT01173926 - Comparison of the Effect of NN5401 With the Effect of NN1250 and Insulin Aspart in Subjects With Type 1 Diabetes | Biotech Hunter

Enrollment

27

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions

DiabetesDiabetes Mellitus, Type 1

Interventions

DRUG

insulin degludec

Each trial participant will receive one single dose of each trial product in varying order (NN5401, NN1250 and insulin aspart) on 3 separate dosing visits. The trial products will be administered subcutaneously (under the skin).

DRUG

insulin degludec/insulin aspart

Each trial participant will receive one single dose of each trial product in varying order (NN5401, NN1250 and insulin aspart) on 3 separate dosing visits. The trial products will be administered subcutaneously (under the skin).

DRUG

insulin aspart

Each trial participant will receive one single dose of each trial product in varying order (NN5401, NN1250 and insulin aspart) on 3 separate dosing visits. The trial products will be administered subcutaneously (under the skin).

Trial Locations (1)

41460

Neuss